Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma

Cardiovascular Toxicology

Volumn 12, Issue 2, 2012, Pages 184-187

  Gupta, Ajay ^a   Pandey, Anvita ^a   Sethi, Sumit ^b  

^a Max Cancer Center   (India)

^b Max Cancer Center ^*  (India)

Author keywords

Bortezomib; Cardiac failure; Multiple myeloma; Reversible

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE; CREATINE KINASE MB; DEXAMETHASONE; DIURETIC AGENT; GLYCERYL TRINITRATE; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PREDNISOLONE; TROPONIN I;

ABNORMAL RESPIRATORY SOUND; AGED; ANAMNESIS; ANEMIA; ANGIOCARDIOGRAPHY; ARTICLE; BACKACHE; BLOOD PRESSURE MEASUREMENT; BLOOD TRANSFUSION; BONE ATROPHY; BONE MARROW BIOPSY; CANCER STAGING; CASE REPORT; CONGESTIVE HEART FAILURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEMOGLOBIN DETERMINATION; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; HYPOKINESIA; LEUKOCYTE COUNT; MULTIPLE MYELOMA; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; PULSE RATE; RESTLESSNESS; SINUS TACHYCARDIA; STENT; THROMBOCYTE COUNT; TREATMENT RESPONSE; TRICUSPID VALVE REGURGITATION; TWO DIMENSIONAL ECHOCARDIOGRAPHY; VENOUS PRESSURE; VERTEBRA COMPRESSION;

AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; FEMALE; HEART FAILURE; HUMANS; MULTIPLE MYELOMA; PYRAZINES;

EID: 84864690566     PISSN: 15307905     EISSN: 15590259     Source Type: Journal    
DOI: 10.1007/s12012-011-9146-7     Document Type: Article

References (12)

1. Adams, J. (2003). Potential for proteasome inhibition in the treatment of cancer. Drug Discovery Today Biosilico, 8, 307-315.
2. Sanchez-Serrano, I. (2006). Success in translational research: lessons from the development of bortezomib. Nature Reviews Drug Discovery, 5, 107-114.
3. Lonial, S., Waller, E. K., Richardson, P. G., et al. (2005). Risk factors and kinetics of thrombocytopenia associated with bort-ezomib for relapsed, refractory multiple myeloma. Blood, 106, 3777-3784.
4. Argyriou, A. A., Iconomou, G., & Kalofonos, H. P. (2008). Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood, 112, 1593-1599.
5. Enrico, O., Gabriele, B., Nadia, C., Sara, G., Daniele, V., Giulia, C., et al. (2007). Unexpected cardiotoxicity in haematological bortezomib treated patients. British Journal Haematology, 138, 396-397.
6. Voortman, J., & Giaccone, G. (2006). Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a nonsmall cell lung cancer patient: a case report. BMC Cancer, 6, 129.
7. Berenson, J. R., Matous, J., Swift, R. A., Mapes, R., Morrison, B., & Yeh, H. S. (2007). A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clinical Cancer Research, 13, 1762-1768.
8. Hacihanefioglu, A., Tarkun, P., & Gonullu, E. (2008). Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. International Journal of Hematology, 88, 219-222.
9. Takamatsu, H., Yamashita, T., Kotani, T., Sawazaki, A., Okumura, H., & Nakao, S. (2010). Ischemic heart disease associated with bortezomib treatment combined with dexamehtasone in a patient with multiple myeloma. International Journal of Hematology, 91, 903-906.
10. Versari, D., Herrmann, J., Gossl, M., Mannheim, D., Sattler, K., Meyer, F. B., et al. (2006). Dysregulation of the ubiquitin-pro-teasome system in human carotid atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 2132-2139.
11. Jancso, G., Cserepes, B., Gasz, B., Benko, L., Ferencz, A., Borsiczky, B., et al. (2005). Effect of acetylsalicylic acid on nuclear factor-kappaB activation and on late preconditioning against infarction in the myocardium. Journal of Cardiovascular Pharmacology, 46, 295-301.
12. Nowis, D., Maczewski, M., Mackieewicz, U., Kujawa, M., Ratajska, A., Wiekowski, M. R., et al. (2010). Cardiotoxicity of the anticancer therapeutic agent bortezomib. American Journal of Pathology, 176, 2658-2668.